Abstract
We report herein the clinical assessment of prostaglandin E1 (PGE1) therapy in congenital heart disease with pulmonary atresia. PGE1CD was administrated to 28 patients and LipoPGE1 was administrated to 20 patients. The dose of PGE1CD was initially 10 ng/kg/min and the dose of LipoPGE1 was initially 5 ng/kg/min. At the onset of infusion, the patients were 13.0±26. 3 days old in the PGE1CD group and 1.7±2.3 days old in the LipoPGE1 group.
We were able to examine the PA-index in 8 cases in the LipoPGE1 group. The mean diameters of right and left pulmonary arteries in these patients increased significantly after the LipoPGE1 therapy. The PA-index also increased significantly. Side effects were observed in 46.4% of the PGE1CD group and in 30.0% of the LipoPGE1 group. In 78.5% of the PGE1CD group and 90.0% of the LipoPGE1 group, the patients survived and were able to undergo surgery.
